BioPharmSignal logoBioPharmSignal

Biotech News

Results from the Phase 3 X-TOLE2 Study Evaluating Azetukalner, a Novel, Potent KV7 Channel Opener, in Adults With Focal Onset Seizures (FOS)

Xenon (XENE)Xenon2026-06-25 13:46 ESTClinical readout

Congress: 2026 Annual Meeting of the American Academy of Neurology (AAN) (April 18-22, 2026) Authors: French, JA et al.

Open original release

Related news

XENEXenon2026-07-02 20:01 EST

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XENEXenon2026-06-25 13:46 EST

Xenon Reports Q1 2026 Financial Results and Provides Business Update

XENEXenon2026-06-25 13:46 EST

Xenon Pharmaceuticals Announces Proposed Public Offering

XENEXenon2026-06-25 13:46 EST

Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering

XENEXenon2026-06-25 13:46 EST

Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

XENEXenon2026-06-25 13:46 EST

Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting

XENEXenon2026-06-25 13:46 EST

Xenon to Present at Upcoming Investor Conferences

XENEXenon2026-06-25 13:46 EST

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XENEXenon2026-06-25 13:46 EST

Xenon to Report Q1 2026 Financial Results on May 7, 2026

XENEXenon2026-06-25 13:46 EST

Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting

View all latest news

Xenon

Xenon is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

XENEZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

XENEZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

XENEBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

XENEGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

XENEMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close
67.72 USD
Market cap
6.66B USD
Exchange
NASDAQ
Sector
Biotechnology
Location
United States